Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IFN-alpha2A Clear all
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

NCT01180790
View directory record Official record
Conditions
Hepatitis C
Interventions
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 17, 2026, 9:17 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

NCT01459913
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Telaprevir, Pegylated Interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2015 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

NCT01853254
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
49
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2013 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 1 Interventional

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

NCT00253474
View directory record Official record
Conditions
Neoplasm of Uncertain Malignant Potential, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
PEG-interferon alfa-2a
Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
1 Year to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes

NCT00001438
View directory record Official record
Conditions
HIV Infections, Immunologic Deficiency Syndromes, Lymphoproliferative Disorders
Interventions
all-trans-retinoic acid with IFN-alpha2a
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 9:17 AM EDT
Terminated Phase 2 Interventional

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

NCT00098618
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
sorafenib tosylate, recombinant interferon alfa, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 17, 2026, 9:17 AM EDT
Terminated Phase 3 Interventional Results available

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

NCT01821963
View directory record Official record
Conditions
Infection
Interventions
Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 69 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 3 Interventional

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

NCT01581203
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Asunaprevir (ASV), Daclatasvir (DCV), Pegylated-interferon alfa 2a (PegIFN), Ribavirin (RBV)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Montgomery, Alabama • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Results available

SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

NCT00083889
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Interferon-alfa, SU011248
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
58
States / cities
Jonesboro, Arkansas • La Jolla, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2010 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging of GSK2336805 in Combination Therapy

NCT01648140
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Ribavirin, Telaprevir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Dothan, Alabama • Anaheim, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

NCT00535847
View directory record Official record
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated interferon alfa 2a
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2014 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Results available

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

NCT01259856
View directory record Official record
Conditions
High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Interventions
PEGASYS, Hydroxyurea, Aspirin
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 17, 2026, 9:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

NCT05756166
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod
Procedure · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 4 Interventional

Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus

NCT00207311
View directory record Official record
Conditions
Fatty Liver, Hepatitis C
Interventions
Xenical, Pegasys, Copegus, Xenicare Program
Drug · Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment

NCT00980330
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, Placebo, Peg-IFN-alfa-2a (P), Ribavirin (R)
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

NCT00059813
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
recombinant interferon alfa, oblimersen sodium, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2013 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma

NCT00000687
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon alfa-2a, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
9
States / cities
Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Treatment of Hepatitis C in Hemophilic Patients With HIV

NCT00055341
View directory record Official record
Conditions
HIV Infections, Hepatitis C, Hemophilia
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Sep 17, 2026, 9:17 AM EDT
Not yet recruiting Phase 2 Interventional

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

NCT07634094
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure
Drug · Biological · Procedure
Lead sponsor
Kalinski, Pawel, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 17, 2026, 9:17 AM EDT
Terminated Phase 2 Interventional

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

NCT00227656
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
PEG-interferon alfa-2a, Capecitabine
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Wichita, Kansas • Grand Rapids, Michigan • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 17, 2026, 9:17 AM EDT
Not listed Phase 1Phase 2 Interventional

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

NCT00423397
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
PEG-interferon alfa-2a, gefitinib
Biological · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 1 Interventional

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

NCT02407080
View directory record Official record
Conditions
Polycythemia Vera, Essential Thrombocythemia
Interventions
RG7388, Pegasys
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New York, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

NCT04585789
View directory record Official record
Conditions
Hepatitis B
Interventions
JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 17, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

NCT00882908
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, Ribavirin (R), PegIFNα-2a (P), Placebo
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Sep 17, 2026, 9:17 AM EDT